Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2026)
26 slides from Csl's shareholder meeting presentation, Oct 27, 2026
Slide 1: CSL Limited Annual General Meeting 2026
27 October, 2026 Melbourne, Australia For personal use only CSL Limited Annual General Meeting 2026 CSL Limited (ASX:CSL; USOTC:CSLLY) will hold its 2026 Annual General Meeting at 10:00am AEDT today in Melbourne. The following is attached for the information of Investors: • the Chair and Interim CEO
Slide 2: Chair Address at the 2026 CSL Annual General Meeting
Chair Address at the 2026 CSL Annual General Meeting Dr Brian McNamee AO, Chair and Independent Non-executive Director Good morning, ladies and gentlemen. Thank you for joining us today, both here in the room and online. There is a quorum present, and it is my pleasure to open the meeting. For perso
Slide 3: Chair Address: CEO appointment and Chair succession
She’s an outstanding global leader with a proven ability to grow complex biopharmaceutical businesses. She has renewed the franchise at ViiV and has dedicated her career to improving outcomes for patients and public health. And she knows the United States well, having previously led GSK’s Vaccine an
Slide 4: Chair Address: Board's four key areas of focus
Markets evolve. Competition increases. Scientific opportunities change. As a result, CSL is already responding and executing more consistently and the Board has four key areas of focus. First, CSL must deliver stronger commercial and operational performance. Second, CSL must improve the productivity
Slide 5: Chair Address: Closing remarks
We remain committed to engaging constructively with shareholders, listening carefully to their views and ensuring that CSL’s remuneration framework supports the long-term interests of the company and its owners. CSL has confronted issues that needed to be addressed. Its strategic priorities are clea
Slide 6: Interim CEO Address: FY26 review
It was also clear from my engagement that the robust and stable industry structure and economics underpinning the plasma business was fundamentally unchanged and that the demand for our key plasma products continued to be strong and growing. However, it was also clear to me that we needed to improve
Slide 7: Interim CEO Address: Transformation progress
Cash generation remains one of the company's greatest strengths and provides flexibility to invest in future growth while maintaining a strong balance sheet and returning capital to shareholders. Across our portfolio, market demand for immunoglobulin therapies remained robust. We also saw strong upt
Slide 8: Interim CEO Address: Capital allocation and R&D
Among the important outcomes of FY26 were our strong cash flows, our disciplined capital allocation and positioning the business for profitable growth Net debt to EBITDA was 1.8 times in FY26, placing leverage comfortably within our target range. A strong balance sheet gives us choices. It allows us
Slide 9: Interim CEO Address: FY27 priorities
Behring and Seqirus are performing well, as expected. We recognise that FY27 is a year where Vifor will continue to face challenges from generic competition in the iron portfolio. We expect additional benefits from the transformation program during FY27 and will continue balancing reinvestment in gr
Slide 10: Interim CEO Address: Company history and thanks
The float, followed by a string of major acquisitions – JRH, ZLB, Nabi and Behring – established the foundations of CSL today and generated enormous value for shareholders and our medical stakeholders. The Novartis Influenza Vaccines acquisition was in the same mould – and was the foundation of Seqi
Slide 11: Welcome to CSL's 2026 Annual General Meeting
rsonal use only WELCOME TO CSL’S 2026 ANNUAL GENERAL MEETING Please ensure your mobile is on silent mode
Slide 12: Legal Notice: Important notice and disclaimer
LEGAL NOTICE Important notice and disclaimer rsonal use only This presentation contains summary information about CSL Limited (ACN 051 588 348) The forward-looking statements are based on CSL's good faith assumptions as to the and its related bodies corporate (together, CSL) and CSL's activities as
Slide 13: Brian McNamee AO, Chair Address
BRIAN MCNAMEE AO Chair and Independent rsonal use only Non-executive Director Address
Slide 14: Board of Directors and Company Secretary
BOARD OF DIRECTORS AND COMPANY SECRETARY rsonal use only Brian McNamee AO Andrew Cuthbertson AO Brian Daniels Carolyn Hewson AO Samantha Lewis Gordon Naylor Chair & Non-executive Non-executive Director Non-executive Director Non-executive Director Non-executive Director Standing for election Directo
Slide 15: Gordon Naylor, Interim CEO Address
GORDON NAYLOR Interim CEO and rsonal use only Managing Director Address
Slide 16: FY26 - A Successful Reset
FY26 - A SUCCESSFUL RESET rsonal use only • Accelerated CSL’s strategic transformation • Strengthened financial discipline • Invested in our commercial capability • Enhanced focus on operational excellence in plasma collection • Operational separation of CSL Seqirus completed • Positioned to return
Slide 17: FY26 Performance
FY26 PERFORMANCE1 • Consistent with May 2026 update • Reported results include one-off pre-tax restructuring costs of $0.8b and impairment rsonal use only and related costs of $7.1b Revenue $15.8b 1% • Robust Ig demand 2,3 Underlying NPATA $3.1b 2% • Strong uptake of ANDEMBRY® and HEMGENIX® Underlyi
Slide 18: Strong Progress on Transformation Initiatives
STRONG PROGRESS ON TRANSFORMATION INITIATIVES rsonal use only Annual pre-tax cost savings • FY26 one-off pre-tax restructuring costs $799m* • FY26 cost savings delivered above target • Majority of savings across R&D, Commercial & Up to ~$550m Medical and Operations • Disciplined approach to reinvest
Slide 19: Operational Excellence
OPERATIONAL EXCELLENCE rsonal use only
Slide 20: Operational Excellence
OPERATIONAL EXCELLENCE rsonal use only Steve Marlow Executive Vice President & General Manager, CSL Plasma Diego Sacristan Chief Commercial Officer Amy Van Buren Chief People Steve Diego Amy Officer Marlow Sacristan Van Buren
Slide 21: Capital Allocation
CAPITAL ALLOCATION rsonal use only • Strong cash flow has significantly de-levered the Balance Sheet US$b Net Debt/EBITDA • Sufficient capacity to support investment in 11.0 2.7 x 3.0 growth opportunities 2.2 x 2.5 • Leverage within target range of 1.5x – 2.0x 10.0 1.8 x 1.8 x 2.0 • $1.5b of debt re
Slide 22: Investing for Future Growth
INVESTING FOR FUTURE GROWTH rsonal use only
Slide 23: FY27 Outlook at FY26 FX Rates
FY27 OUTLOOK AT FY26 FX RATES rsonal use only FY27 Guidance Reaffirmed Revenue In-line with FY26 @CC1 Underlying NPAT4 Growth ~5% @CC1,3 FX impact estimated to be a headwind of ~$50m if current rates remain unchanged for the remainder of the Financial Year Anticipated FY27 impairments ~$200m
Slide 24: Priorities for FY27: Focused on Execution
PRIORITIES FOR FY27 FOCUSED ON EXECUTION rsonal use only Drive portfolio Lead in operational Enable and elevate innovation and growth excellence our people Improve commercial Deliver Build the performance and transformation capability and returns from benefits and accountability R&D and business inc
Slide 25: Appendix: Footnotes
APPENDIX FOOTNOTES rsonal use only 1. Percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. 2. Underlying NPATA represents the statutory net (loss) / profit after tax before amortisation of acquired IP and signi
Slide 26: Thank You
rsonal use only THANK YOU 2026 ANNUAL GENERAL MEETING